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Abstract
Background: A prospective observational
study was undertaken in 2,481 patients un-
dergoing elective colon resection in 114 Ger-
man centers to identify optimal drug and
dosing modalities and risk factors for postop-
erative infection. Methods: Patients were
pair matched using six risk factors and di-
vided into 672 pairs (ceftriaxone vs. other
cephalosporins, group A) and 400 pairs (cef-
triaxone vs. penicillins, group B). End points
were local and systemic postoperative infec-
tion and cost effectiveness. Results: Local
infection rates were 6.0 versus 6.5% (group
A) and 4.0 versus 10.5% (group B); systemic
infection rates in groups A and B were 4.9
versus 6.3% and 3.3 versus 10.5%, respec-
tively. Ceftriaxone was more effective than
penicillins overall (6.8 vs. 17.8%, p ! 0.001).
Length of postoperative hospital stay was
16.2 versus 16.9 days (group A) and 15.8 ver-
sus 17.6 days (group B). Of the six risk fac-
tors, age and concomitant disease were sig-
nificant for systemic infection, and blood
loss, rectum resection and immunosuppres-
sive therapy were significant for local infec-
tion. Penicillin was a risk factor compared to
ceftriaxone (p ! 0.0001). Ceftriaxone saved
C=160.7 versus other cephalosporins and
C=416.2 versus penicillins. Conclusion: Clini-
cal and microbiological efficacy are responsi-
ble for the cost effectiveness of ceftriaxone
for perioperative prophylaxis in colorectal
surgery.
Copyright © 2000 S. Karger AG, Basel
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Introduction
The use of antibiotics for perioperative
prophylaxis in colorectal surgery is now gener-
ally undisputed, although debate continues on
the optimal choice of drug(s) and administra-
tion modalities. Efficacy can only be assessed
by reviewing the overall incidence of peri-
operative bacterial complications (including
related mortality) and not simply the wound
infection rate. For this reason, prophylaxis is
best evaluated in terms of postoperative risk
prevention. The more effective the prophy-
laxis, particularly against secondary infec-
tious complications (e.g. pneumonia), the
greater the decrease not only in surgical risk
but also in cost, in terms of staff time, drugs,
laboratory investigations, use of equipment,
(re)operation and length of hospital stay.
Third-generation cephalosporins are high-
ly effective against gram-negative intestinal
bacteria. Ceftriaxone, which is particularly
suited to postoperative prophylaxis due to its
sustained duration of activity, was compared
in this observational study to other beta-lac-
tams (cephalosporins and penicillins) with re-
spect to postoperative risk prevention and
cost effectiveness in a large patient population
under routine practice conditions.
Patients and Methods
This prospective observational study on periopera-
tive infection prophylaxis was conducted between Sep-
tember 1, 1996 and September 30, 1997 in Germany
in 2,513 patients undergoing elective colon resection in
114 centers.
Patients
Exclusion criteria were suppurative peritonitis,
other preexisting infections requiring antibiotic thera-
py, emergency surgery, mechanical ventilation for
more than 12 h, granulocytopenia (!1,000/mm3) and
autoimmune deficiency syndrome.
Table 1. Patient distribution
Patient status Patients
2,513
Protocol violators 32
Evaluable 2,481
Post-matching
Ceftriaxone/other cephalosporins1
(group A)
672/672
Ceftriaxone/broad-spectrum
penicillin2 (group B)
400/400
Unmatched 337
1 Cefotiam (n = 270); cefazolin (n = 130); cefoxitin
(n = 66); cefotaxime (n = 31).
2 Mezlocillin (n = 168); amoxicillin/clavulanic acid
(n = 106); ampicillin/sulbactam (n = 104); miscella-
neous (n = 22).
End Points
The end points of the study were clinical efficacy
(no local or systemic infection in the first 10 postopera-
tive days) and cost effectiveness measures (pre- and
postoperative antibiotic therapy and length of postop-
erative hospital stay). Local infectious complications
consisted of the following: suppurating wound; abscess
(localized or diffuse); peritonitis, and suture failure.
Systemic complications comprised: pneumonia and
other respiratory tract infection; urinary tract infec-
tion; venous catheter infection, and sepsis. Subana-
lyses examined the impact of risk factors on local and
systemic postoperative infection rates.
Antibiotic Prophylaxis
As befits an observational study, the choice of anti-
biotics and administration modalities was left to the
practitioners, who followed their departmental prac-
tice. The recommended schedule for ceftriaxone was a
single preoperative dose supplemented by metronida-
zole for anaerobe cover.
Statistical Analysis
Statistical analysis (Factum GmbH, Offenbach/
Main, Germany) was performed using SPSS for Win-
dows, release 6.1.3 (October 1995). Descriptive p val-
ues were calculated using McNemar’s test or a t test for
paired samples. To exclude bias, patients were risk
matched into pairs using the following six criteria:
operation duration (! or 12 h); blood loss (! or 13 red
Age 165 years
Age, years
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Table 2. Group distribution (%) of main risk factor matching criteria
Criterion Group A Group B
(672 pairs) (400 pairs)
58.3 56.3
Operation duration 12 h 65.3 58.3
Blood loss 13 red cell concentrates 1.8 3.8
Colon + rectum resection 20.1 19.3
Preexisting diabetes mellitus, hepatic, renal or airways disease 33.4 37.3
Immunosuppressive therapy or radiation 3.6 1.8
Table 3. Group demographics, preoperative diagnosis and concomitant disease
Parameter Group A (672 pairs)
ceftriaxone other
cephalosporins
Group B (400 pairs)
ceftriaxone penicillins
65.9 66.1 65.4 66.0
Height, cm 168.5 167.7 168.7 169.0
Weight, kg 72.6 72.1 73.0 73.9
Sex (male), % 49.1 45.2 46.8 48.0
Colon carcinoma, % 65.8 69.9 66.0 73.0
Diverticulitis, % 18.6 14.7 18.3 15.5
Crohn’s disease, % 1.8 0.9 1.5 1.3
Ulcerative colitis, % 1.9 0.9 2.5 0.5
Preexisting ileus/severe intestinal stenosis, % 15.0 12.5 14.8 11.8
Preexisting colostomy, % 7.1 5.4 6.5 2.8
Prior abdominal surgery, % 4.8 4.3 3.8 3.0
Concomitant disease, % 63.1 64.1 68.3 64.0
Cardiovascular, % 46.4 43.5 50.0 46.0
Diabetes mellitus, % 12.4 13.9 13.0 16.0
Chronic airways, % 11.9 9.8 15.8 10.0
Obesity, % 10.9 11.3 14.0 13.0
cell concentrates); colon resection plus rectum resec-
tion (yes/no); age (! or 165 years); preexisting diabetes
mellitus, hepatic, renal or airway disease (yes/no); im-
munosuppressive therapy (e.g. steroids) or radiation
(yes/no). Patients paired for all six criteria were as-
signed to group A (ceftriaxone vs. other cephalospo-
rins) or group B (ceftriaxone vs. penicillin).
Risk analysis to validate the matching criteria was
performed in the total evaluable population (n = 2,481)
after excluding protocol violators (n = 32). Antibiotic
regimes were tested in this population for their impact
on postoperative infection rates and the results were
expressed as odds ratios (OR). A significance level of
p ! 0.05 was used in all tests.
Patient Groups
Group A comprised 1,344 patients and group B
800 patients (table 1). The distribution of the six
matching risk factors is shown in table 2. Groups A
and B did not differ in respect to demographics, preop-
erative diagnosis, risk factors or type of colon resection
(tables 3–5). 
Cecum and ascending colon
Operation duration, min
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Table 4. Type of colon resection (%) in groups A and B
Colon resection Group A (672 pairs)
ceftriaxone other
cephalosporins
Group B (400 pairs)
ceftriaxone penicillins
23.5 25.6 24.0 25.0
Transverse colon 6.6 4.9 5.5 8.0
Descending colon 14.9 13.2 11.5 11.5
Sigmoid colon 32.9 39.0 37.3 37.8
With protective colostomy/ileostomy 8.1 9.9 8.1 8.6
Rectum (deep anastomosis)1 20.1 20.1 19.3 19.3
With protective colostomy/ileostomy 17.8 23.0 19.5 15.6
Other colon surgery 16.5 16.1 17.0 12.3
Creation of colostomy 8.9 7.7 7.8 7.8
Colostomy reversal 5.8 3.4 4.8 2.3
1 Matching criterion.
Table 5. Nonmatching operative risk factors in groups A and B
Risk factor Group A (672 pairs)
ceftriaxone other
cephalosporins
Group B (400 pairs)
ceftriaxone penicillins
153 156 147 148
Blood loss, ml 423 467 436 460
Clean bowel, % 94.5 91.2 91.8 92.3
Intraoperative bowel irrigation, % 4.6 4.6 4.3 5.8
Stapler anastomosis, % 34.1 39.1 36.8 27.5
Abdominal drainage, % 86.9 89.6 87.3 91.8
Dosage and Concomitant Prophylaxis
Antibiotics and administration modalities are
shown in tables 6 and 7. Ceftriaxone was administered
in 90% of cases as a single preoperative 2-gram dose.
The average duration of prophylaxis with the other
beta-lactams was 2–3 days. Only amoxicillin/clavu-
lanic acid was administered for a shorter period, i.e.
1.36 days. In group A, concomitant metronidazole was
given to 62.2 and 80.5% of ceftriaxone and other
cephalosporin patients, respectively, and in group B, to
66.3 and 51.0% of ceftriaxone and penicillin patients,
respectively. Concomitant gentamicin was given to
4.9% of other cephalosporin patients and 1% of peni-
cillin patients. Other concomitant antibiotic therapy
was given to 1.7% of ceftriaxone patients and 0.6% of
other cephalosporin patients in group A and 0.8% of
both subgroups in group B.
Standard Microbiology
This was performed intraoperatively for suspected
infection and in postoperative infections.
Ceftriaxone
Ceftriaxone
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Table 6. Antibiotic dosage and
administration modalities in
group A
Antibiotic Schedule Frequency
of use, %
Mean
dose, g
Duration
days
1.99 1.49
1 ! 2 g 90.3
Cefotiam 2.90 2.33
1 ! 2 g 67.4
2 ! 2 g 11.1
3 ! 2 g 13.3
Cefuroxime 2.49 2.41
1 ! 1.5 g 53.1
2 ! 1.5 g 12.6
3 ! 1.5 g 20.0
Cefazolin 3.25 1.99
1 ! 2 g 58.5
2 ! 2 g 20.8
3 ! 2 g 20.8
Table 7. Antibiotic dosage and
administration modalities in
group B
Antibiotic Schedule Frequency
of use, %
Mean
dose, g
Duration
days
2.00 1.48
1 ! 2 g 89.3
Mezlocillin 4.77 2.17
1 ! 2 g 25.6
1 ! 4 g 25.6
3 ! 2 g 31.0
Amoxicillin/clavulanic acid 2.49 1.36
1 ! 2.2 g 74.5
2 ! 2.2 g 9.4
Ampicillin/sulbactam 5.61 2.64
1 ! 3 g 51.0
3 ! 3 g 26.0
Results
Clinical Results
The rates of infectious complications in the
first 10 postoperative days were 10.0% with
ceftriaxone versus 10.9% with other cephalo-
sporins in group A, and 6.8 versus 17.8% with
ceftriaxone versus penicillin in group B (ta-
ble 8). Physicians’ impressions rated prophy-
laxis effective in 92.4 and 83.8% of ceftriax-
one and other cephalosporin patients in group
A, and in 91.8 and 83.3% of ceftriaxone and
Local complications
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Table 8. Infectious complications (n) in the first 10 postoperative days
Complication Group A (672 pairs)
ceftriaxone other
cephalosporins
Group B (400 pairs)
ceftriaxone penicillins
Suppurating wound 22 20 11 18
Abscess 7 11 2 9
Peritonitis 2 3 0 4
Suture failure 9 10 3 11
Total local complications 40 (6.0) 44 (6.5) 16 (4.0) 42 (10.5)
Systemic infections
Pneumonia 7 16 6 14
Other respiratory tract infections 3 3 1 1
Urinary tract infection 17 18 4 18
Venous catheter infection 5 3 2 6
Sepsis 1 1 0 3
Other systemic infection 0 1 0 0
Total systemic infections 33 (4.9) 42 (6.3) 13 (3.3) 42 (10.5)
Total infection rate 67 (10.0) 73 (10.9) 27 (6.8) 71 (17.8)*
Figures in parentheses represent percentages. * p ! 0.001 for ceftriaxone versus penicillin.
penicillin patients in group B. Adverse events
(whether related to antibiotics or not) oc-
curred in fewer than 5% of cases: 4.5 and
3.9% in the ceftriaxone and other cephalospo-
rin subgroups, respectively, in group A, and
4.3 and 3.0% in the ceftriaxone and penicillin
subgroups, respectively, in group B. There
were 0 and 4 postoperative inpatient deaths in
the ceftriaxone and other cephalosporin sub-
groups, and 1 and 2 in the ceftriaxone and
penicillin subgroups.
Microbiology
Postoperative pathogens were markedly
fewer with ceftriaxone compared to other an-
tibiotics: 23 versus 45 gram-positive isolates,
and 28 versus 58 gram-negative isolates, re-
spectively (table 9). Gram-negative infection
rates were lower with ceftriaxone than with
other cephalosporins. The rates of both gram-
negative and gram-positive infections were
lower with ceftriaxone than with penicil-
lin. Pathogen distribution in postoperative
wound and airway infections (table 10)
showed a majority of Escherichia coli and oth-
er Enterobacteriaceae, followed by staphylo-
cocci, enterococci and Pseudomonas spp. No
airway or wound infections due to Pseudo-
monas spp. occurred with ceftriaxone. There
were also fewer enterococcal and staphylococ-
cal wound infections with ceftriaxone than
with penicillin (1 vs. 4, and 4 vs. 9, respec-
tively).
Risk Analysis
Rectum resection (OR = 1.55, p = 0.022)
and concomitant disease (OR = 1.65, p =
0.0001) were prognostically significant risk
Airways
Respiratory tract
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Table 9. Postoperative gram-positive/gram-negative infections (n)
Sample site Group A (672 pairs)
ceftri-
axone
other
cephalosporins
Group B (400 pairs)
ceftri-
axone
peni-
cillins
1/2 1/6 0/0 3/2
Blood 0/2 0/0 0/1 2/1
Wound 12/11 13/21 6/8 13/14
Urine 3/2 4/6 1/2 9/8
ntotal 16/17 18/33 7/11 27/25
Total pathogens (n = 154) 33 51 18 52
Table 10. Pathogen distribution (n) in postoperative wound and respiratory tract infections
Isolate Group A (672 pairs)
ceftri-
axone
other
cephalosporins
Group B (400 pairs)
ceftri-
axone
peni-
cillins
Enterobacteriaceae 2 1 0 2
Pseudomonas spp. 0 4 0 0
Other 1 2 0 3
Wound
Staphylococci 3 3 4 9
Enterococci 7 9 1 4
Escherichia coli 5 10 3 9
Other Enterobacteriaceae 3 4 3 2
Pseudomonas spp. 0 4 0 1
Bacteroides spp. 3 2 2 2
Other bacteria 2 2 1 0
factors for postoperative infection (table 11).
Further analysis showed age and concomitant
disease to be significant risk factors for sys-
temic complications, while blood loss, rectum
resection and immunosuppressive therapy
were significant risk factors for local compli-
cations. Operation duration of more than 2 h
was associated with a nonsignificant increase
in postoperative complications (table 12).
Five of the six matching criteria significantly
impacted on the postoperative infection rate,
thereby confirming their suitability for un-
biased patient pairing.
Testing antibiotic regimes for an impact on
postoperative infection in the total population
showed penicillin to be a significant risk fac-
tor compared to ceftriaxone (OR = 2.18, p !
0.0001), and prophylaxis without metronida-
zole for anaerobe cover (OR = 1.79, p !
0.0001). Analysis of the individual antibiotic
Age ^ /165 years
Age ^ /165 years
Postoperative antibiotic therapy
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Table 11. Risk factors for postoperative infection
Risk factor Infection, % OR p
10.7/12.1 1.15 0.265
Operation duration ^/12 h 10.0/12.4 1.28 0.063
Blood loss ^ /13 red cell concentrates 11.3/17.6 1.70 0.064
Colon + rectum resection (no/yes) 10.5/15.4 1.55 0.022
Concomitant disease (no/yes) 15.6/10.0 1.65 0.0001
Immunosuppressive therapy (no/yes) 11.2/17.1 1.63 0.063
Ceftriaxone/other cephalosporins 9.3/11.0 1.21 0.214
Ceftriaxone/penicillin 11.0/18.3 1.80 0.0005
Ceftriaxone +/– metronidazole 7.7/11.8 1.61 0.012
Other cephalosporins +/– metronidazole 9.6/17.0 1.93 0.014
Penicillin +/– metronidazole 13.8/22.7 1.84 0.013
Table 12. Risk factors for local and systemic postoperative infection
Risk factor Local
infection, %
p Systemic
infection, %
p
6.8/5.7 0.239 4.5/6.8 0.014
Operation duration ^/12 h 5.2/6.9 0.082 5.1/6.2 0.222
Blood loss ^ /13 red cell concentrates 5.9/14.3 0.001 5.8/5.5 0.908
Colon + rectum resection (no/yes) 5.6/8.8 0.007 5.5/7.0 0.185
Concomitant disease (no/yes) 5.8/7.3 0.199 4.5/9.3 !0.001
Immunosuppressive therapy (no/yes) 5.9/13.3 0.002 5.8/5.7 0.982
Table 13. Main postoperative cost factors
Factor Group A (672 pairs)
ceftriaxone other
cephalosporins
Group B (400 pairs)
ceftriaxone penicillin
83 (12.4) 110 (16.4) 46 (11.5) 100 (25.0)
Mechanical ventilation
(from 1st postoperative day) 2 (0.3) 4 (0.6) 0 2 (0.5)
Reoperation 34 (3.6) 26 (3.9) 9 (2.3) 14 (3.5)
Hospital stay (days) 16.2 16.9 15.8 17.6*
Figures in parentheses represent percentages. * p ! 0.001 for ceftriaxone versus penicillin.
Infection Prophylaxis and Risk Factors
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regimes confirmed the necessity of concomi-
tant metronidazole with both cephalosporins
and penicillin in elective colon surgery (ta-
ble 11).
Cost Effectiveness
Differences in prophylactic efficacy are re-
flected in the incidence and severity of local
and systemic postoperative infection, postop-
erative antibiotic requirements, admission to
intensive care (with or without mechanical
ventilation) and reoperation. The main differ-
ences found in the present study in the rela-
tionship between prophylactic regime and
postoperative complications were in postop-
erative antibiotic requirements and duration
of hospital stay (table 13). Ceftriaxone short-
ened hospital stay (by 0.7 days in group A,
and by 1.8 days in group B). Using a daily rate
of C= 229.6 for inpatients (general rate plus a
20% departmental rate in the surgical depart-
ment of the Munich-Grosshadern Hospital,
1997), ceftriaxone saved C= 160.7 over other
cephalosporins and C= 413.2 over penicillin.
Although the cost of reoperation, an un-
doubtedly substantial factor, was not calcu-
lated due to the complexities involved, it was
partly covered in costing the length of postop-
erative stay.
Discussion and Conclusions
The First (German) National Prevalence
Study (NIDEP) showed that wound infection
is only the third most common type of noso-
comial infection (15.1%) [1], preceded by in-
fection of the urinary tract (40.2%) and lower
airways (19.7%). Wound infection only be-
comes significant when it requires reopera-
tion, as with deep-seated infection or abscess
formation. Secondary systemic infection, on
the other hand, almost always prolongs hospi-
tal stay. Postoperative pneumonia and septi-
cemia always involve serious illness and in-
creased mortality. Preoperative prophylaxis
should thus aim at effective postoperative risk
prevention by decreasing postoperative sys-
temic complications as well as wound infec-
tion.
The risk of postoperative secondary infec-
tion does not end with the tying of the last
suture. The risk of postoperative pneumonia
increases with the duration of intubation
anesthesia and postoperative ventilation.
Many factors affect individual risk, e.g. pain,
ileus and chronic lower airways disease. Uri-
nary tract infection increases with postopera-
tive retention or catheter drainage. Effective
antibiotic levels thus need to be sustained
over the early postoperative risk period to
decrease complications, primarily systemic
infection. The advantage of a long-acting
cephalosporin such as ceftriaxone is that a sin-
gle preoperative dose provides 24 h of cover.
Prophylaxis with short-acting antibiotics, on
the other hand, requires 2–3 doses over the
same period. In addition to duration of activi-
ty, the microbiological spectrum is also an
important consideration in selecting an anti-
biotic for visceral and abdominal surgery,
which requires maximal cover against gram-
negative bacteria, primarily E. coli, but also
other Enterobacteriaceae. Third-generation
cephalosporins have significant advantages in
this regard over conventional cephalosporins
and particularly over penicillin [2].
Our data do not indicate whether the great-
er efficacy of ceftriaxone (nonsignificant vs.
other cephalosporins, significant vs. penicil-
lin) was due to longer duration of activity and/
or a broader spectrum. The study was obser-
vational and comprised only a recommenda-
tion for 24 h of prophylaxis. The design left
the choice of dosage to the physician. The effi-
cacy of a single dose of ceftriaxone is probably
due to the drug’s specific pharmacokinetic
profile, which ensures bactericidal concentra-
First and second (n = 1,079)
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Table 14. Wound infection rates and preoperative
prophylaxis with different generations of cephalospo-
rin [6]
Cephalosporin generation Wound infection
rate, %
14.8
Third (n = 340) 7.9
tions against susceptible organisms for 24 h.
In a report on the Dutch Trauma Trial, the
authors noted that the mean serum concentra-
tion of 2 g of ceftriaxone 1 h after administra-
tion was 177 mg/l – well above the minimum
inhibitory concentration for microorganisms
causing infections in accident surgery [3]. Cef-
triaxone also attains good tissue concentra-
tions and can even demonstrate high bacteri-
cidal concentrations in bile in the case of cho-
lestasis [4]. A matter for discussion is whether
the tissue concentration in addition to the
local concentration in the bowel might be
effective in the prophylaxis of anastomosis
insufficiency. An analogous mechanism has
been demonstrated for preventing leakage of
esophago-intestinal anastomosis [5].
A further result of our study is an overall
view of the prophylactic regimes currently
used for colon surgery in Germany. The treat-
ment duration of ceftriaxone was only 1.5
days (median), compared to 2–3 days for the
comparators (except amoxicillin/clavulanic
acid). Its superiority is thus more likely to be
due to a more potent spectrum than to a lon-
ger duration of activity.
A 1991 literature review [6] concluded
that, at least in colon surgery, third-generation
cephalosporins appeared to be clinically more
effective than first- and second-generation ce-
phalosporins, and thus display a better cost/
benefit ratio (table 14).
In a prospective randomized double-blind
study of perioperative prophylaxis with cef-
triaxone 2 g B metronidazole versus cefazolin
1 g + metronidazole in colorectal surgery [7],
postoperative airway and urinary tract infec-
tions were more frequent with cefazolin (p !
0.01). All the deaths were in the cefazolin
group, and all resulted from postoperative
sepsis. Other studies have also reported great-
er efficacy with ceftriaxone in colon surgery
[8–10]. In particular, a meta-analysis of 43
randomized comparative studies of perioper-
ative prophylaxis with single-dose ceftriaxone
versus other cephalosporins in a total of
13,482 patients found lower overall rates of
infection with ceftriaxone – by 30% in wound
infections, 47% in urinary tract infections and
19% in respiratory tract infections [11].
Our study did not address the impact of
concomitant metronidazole. Although in one
study, the authors concluded that it is not
always necessary to give metronidazole in ad-
dition to ceftriaxone for perioperative pro-
phylaxis [7], many authors have recom-
mended this combination as advantageous [8,
9]. In the present study, metronidazole was
combined with ceftriaxone in approximately
65% of cases, compared to 80% with other
cephalosporins and only approximately 50%
with penicillin. The results of our risk analysis
also confirm that metronidazole needs to be
administered with all beta-lactams, since
postoperative infectious complications were
significantly reduced in each case.
Detailed studies have already shown that
effective antibiotic prophylaxis not only en-
hances postoperative outcome but also sub-
stantially lowers costs [12, 13]. It is thus not
surprising that in our study, the greater over-
all efficacy of prophylaxis with ceftriaxone
versus other beta-lactams in colon resection
decreased costs by decreasing the postopera-
tive infection rate.
Infection Prophylaxis and Risk Factors
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